Federated Hermes
OVID icon

Federated Hermes’s Ovid Therapeutics OVID Stock Holding History

Federated Hermes’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.93M Hold
3,571,000
– – 0.01% 701
2025
Q4 		$5.31M Buy
+3,571,000
New +$5.5M 0.01% 773
2024
Q3 		– Sell
-2,250
Closed -$1.73K – 2135
2024
Q2 		$1.73K Buy
+2,250
New +$6.26K ﹤0.01% 1909
2022
Q1 		– Sell
-1,887
Closed -$6K – 2277
2021
Q4 		$6K Buy
1,887
+656
+53% +$2.25K ﹤0.01% 1980
2021
Q3 		$4K Buy
1,231
+981
+392% +$3.58K ﹤0.01% 2057
2021
Q2 		$1K Buy
+250
New +$987 ﹤0.01% 2148
2021
Q1 		– Sell
-483
Closed -$1K – 2323
2020
Q4 		$1K Sell
483
-1,775
-79% -$8.27K ﹤0.01% 2187
2020
Q3 		$13K Buy
2,258
+2,037
+922% +$13.6K ﹤0.01% 1940
2020
Q2 		$2K Sell
221
-1
-0.5% -$5 ﹤0.01% 2087
2020
Q1 		$1K Sell
222
-98
-31% -$330 ﹤0.01% 2140
2019
Q4 		$1K Buy
+320
New +$1.01K ﹤0.01% 2126

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Federated Hermes's OVID Position: Q1 2026 in Review

Federated Hermes held its Ovid Therapeutics (OVID) position steady in Q1 2026 at 3,571,000 shares worth $7.93M. The position accounts for 0.01% of the portfolio, ranked #701.

Federated Hermes first reported a position in OVID in Q4 2019 and has held it in 11 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Federated Hermes held 3,571,000 shares of Ovid Therapeutics worth $7.93M as of Q1 2026.
  • Federated Hermes left its Ovid Therapeutics share count unchanged in Q1 2026.
  • Ovid Therapeutics made up 0.01% of Federated Hermes's portfolio in Q1 2026, its #701 holding.
  • Federated Hermes first reported a position in Ovid Therapeutics in Q4 2019 and has held it in 11 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.